Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis.
Hannah BowerThomas FrisellDaniela di GiuseppeBénédicte DelcoigneJohan AsklingPublished in: RMD open (2023)
As used in present clinical practice in Sweden, we found no evidence that CV risk is higher with JAKis than TNFis in RA.